Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peri-operative doxorubicin-based chemotherapy in CINSARC high-risk localized grade 1–2 soft tissue sarcoma
2019-003014-13Phase 3Active
- Sponsor
- Institut Claudius Regaud
- Start
- Dec 2019
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of doxorubicin, ifosfamide and dacarbazine in soft tissue sarcoma (STS) (2 arms), sponsored by Institut Claudius Regaud. Primary endpoint: Metastasis-free survival. Started Dec 2019; status: active.
02
Drugs
doxorubicinifosfamidedacarbazine
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2019-003014-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003014-13.